Swiss Federal Institute of Technology in LausanneSwitzerland
Brian W. Pogue, Ph.D., is the Robert A. Pritzker Chair in Biomedical Engineering at Dartmouth College's Thayer School of Engineering, with a joint appointment as an Honorary Fellow in Medical Physics at the University of Wisconsin-Madison. His academic background includes a Ph.D. in Medical/Nuclear Physics from McMaster University and a Research Fellowship at Harvard Medical School's Wellman Center for Photomedicine. He has led significant administrative roles, including Dean of Graduate Studies at Dartmouth (2008–2012) and Chair of Medical Physics at Wisconsin (2022–2025). Research Focus : Dr. Pogue pioneers Optics in Medicine , specializing in cancer imaging, photodynamic therapy, and surgical guidance. His work integrates fluorescence imaging, radiation therapy monitoring, and molecular diagnostics to improve cancer treatment precision. Key innovations include Cherenkov imaging for radiotherapy dosimetry and hypoxia-sensitive probes for tumor resection. Publication Trends : Recent articles (2023–2025) emphasize real-time surgical guidance, hypoxia quantification, and multimodal imaging systems. Dominant themes include fluorescence tomography, radiation dosimetry, and low-cost diagnostic devices, reflecting a translational focus from preclinical validation to clinical applications. Awards & Honors : Fellow, Optica (formerly OSA) Fellow, American Institute for Medical and Biological Engineering (AIMBE) Fellow, American Association of Physicists in Medicine (AAPM) Fellow, SPIE (International Society for Optics and Photonics) Funding & Innovation : Continuously funded by the NIH since 2001 ($52M+ total), Dr. Pogue founded three startups: DoseOptics LLC (radiotherapy dose imaging) and Hypoxia Surgical LLC (tissue hypoxia cameras), bridging academic research to clinical tools.
Sinead O'Keeffe is a Research Fellow at the University of Limerick in the Faculty of Science and Engineering , specifically within the Department of Electronic and Computer Engineering . Her research bridges the technical domain of optical fiber sensor development with critical applications in radiation therapy and sports medicine. Primary Research Themes Medical radiation dosimetry using optical fiber sensors Brachytherapy dose monitoring systems Sports injury prevention in Gaelic football and running Mental health literacy in rural farming communities Key Technical Contributions Development of scintillation-based dosimeters Characterization of perfluorinated polymer fibers 3D printed sensor systems for clinical and rehabilitation applications Interdisciplinary Applications Prostate cancer radiotherapy dose measurement Mental health intervention programs for athletes Work-family conflict analysis in Irish farming Email: sinead.okeeffe@ul.ie
Professor Richard De Abreu Lourenco is affiliated with the University of Technology Sydney (UTS) as a faculty member in the Faculty of Health , specifically within the Centre for Health Economics Research and Evaluation (CHERE) since 2024. Previously, he held academic roles at UTS including Associate Professor (2018-2023), Senior Research Fellow (2016-2018), and Research Fellow (2013-2016). His non-academic career includes leadership roles at Covance (2006-2013) and Novartis Pharmaceuticals (2001-2006). Education: PhD, University of Technology Sydney (2017) Master of Economics, University of Sydney (1997) Bachelor of Economics, Murdoch University (1992) Research Focus: His work spans applied economic evaluations , specialty health economics (particularly oncology/haematology ), patient preference modeling , and priority setting in healthcare . He explores cost-effectiveness of emerging therapies (CAR-T, SABR radiotherapy), health technology assessment (HTA) , and value frameworks for high-cost treatments . Recent Trends: Recent publications analyze access pathways for rare disease drugs , methodological challenges in discrete choice experiments , cost-effectiveness of radiotherapy vs. ablation , and genetic risk stratification in endocrine tumors . Collaborative work spans oncology , public health policy , and diagnostic testing preferences . Supervision & Grants: Available for Masters and PhD supervision . Leads funded research projects including generative AI in pharmaceutical evaluation , digital health for culturally diverse prostate cancer patients , and economic frameworks for high-cost therapies . Collaborates with institutions like Novartis , Covance , and Cancer Australia .
Louis S. Constine, M.D. is a Professor and Philip Rubin Professor of Radiation Oncology at the University of Rochester Medical Center's School of Medicine and Dentistry. He is a radiation oncologist with clinical and scientific expertise in lymphomas, sarcomas, all pediatric malignancies, and cancer survivorship, particularly focusing on the acute and chronic effects of chemotherapy and radiation therapy on normal tissues. Dr. Constine is actively involved in multiple national and international cancer research groups and is currently accepting new patients at the Wilmot Cancer Center in Rochester, NY. MD from Johns Hopkins University School of Medicine (1973) Residency in Radiation Oncology, Stanford University Medical Center (1978-1981) Fellowship in Pediatric Hematology-Oncology, Seattle Children's Hospital (1976-1978) Residency in Pediatrics, Stanford University Medical Center (1975-1976) Residency in Pediatric Genetics, UCSF Medical Center Moffitt-Long Hospitals (1973-1975) Dr. Constine's research primarily focuses on the long-term effects of radiation therapy in pediatric cancer survivors, with special emphasis on normal tissue complications. His work spans radiation dosimetry, late effects management, and survivorship guidelines development. He has been instrumental in establishing international standards for monitoring and preventing radiation-induced complications in childhood cancer survivors through his leadership in the Pediatric Normal Tissue Effects in the Clinic (PENTEC) initiative. His research has significantly contributed to understanding the dose-volume relationships for various normal tissues in children receiving radiation therapy. His recent publications (2024-2025) demonstrate a strong focus on comprehensive reviews of late effects in childhood cancer survivors through the PENTEC initiative, covering multiple organ systems including thyroid, kidney, metabolic syndrome, neurocognitive effects, and more. His work also includes clinical trials for pediatric Hodgkin lymphoma, innovative approaches to radiation therapy delivery (such as audiovisual immersion techniques), and international collaborations developing standardized surveillance guidelines for cancer survivors. The breadth of his publications shows his leadership in translating research findings into practical clinical guidelines for long-term follow-up care. Dr. Constine has received numerous prestigious awards throughout his career, reflecting his contributions to both clinical care and research: Educator of the Year (2018, 2011) America's Most Honored Professionals--Top 1% (2017) Albert Nelson Marquis Lifetime Achievement Award (2017-2018) Philip Rubin Professor of Radiation Oncology and Pediatrics (2013) Patient- and Family-Centered ICARE High Performance Award (2012-2013) Multiple teaching awards including the Philip Rubin-Mayer Mitchell Teaching Award (2005, 2001, 1997) America's Top Doctors for Cancer (2007-2017) Dr. Constine serves as the Radiation Chair of the Lymphoma Committee in the Southwest Oncology Group and holds leadership positions in multiple national and international organizations focused on childhood cancer survivorship. He chairs the Pediatric Quantitative Analysis of Normal Tissue Effects in the Clinic ASTRO/AAPM initiative and serves on the Children's Oncology Group Late Effects Steering Committee. His grant funding includes an ROI evaluating long-term cardiac toxicities in Hodgkin lymphoma survivors and membership on the steering committee for the NCI-supported Childhood Cancer Survivorship Study. His international work includes participation in United Nations task forces on radiation effects in children and International Atomic Energy Agency initiatives for pediatric radiation oncology in low-income countries. Dr. Constine leads the Pediatric Normal Tissue Effects in the Clinic (PENTEC) initiative, an international collaboration that has produced numerous comprehensive reviews on radiation dose-volume-response relationships for children with cancer. Through this work, he has established himself as a world leader in understanding and mitigating the late effects of radiation therapy in pediatric cancer survivors. His collaborative efforts span multiple institutions and countries, focusing on developing evidence-based guidelines for long-term follow-up care of childhood cancer survivors.
Institute of Hygiene and Tropical MedicinePortugal
Professor Ajay Aggarwal is a leading academic in Cancer Services and Systems Research at the London School of Hygiene & Tropical Medicine (LSHTM) and a Consultant Clinical Oncologist at Guy’s & St Thomas’ NHS Trust. His work bridges clinical practice and health policy, focusing on cancer care quality, global health equity, and innovative technologies like AI in radiotherapy. PhD, LSHTM MSc, LSHTM (Health Services Research) MSc, Institute of Cancer Research (Cancer Science) BSc, King’s College London (Medicine) BSc, Imperial College London (Management) His research explores cancer policy, performance assessment of cancer care, and global health systems. He employs mixed methods to analyze large clinical datasets, addressing affordability of cancer care, value of technologies, and health disparities. His work influences WHO taskforces and European cancer policy. Recent publications span quality improvement (e.g., national cancer audits), global health equity (e.g., Zambia cancer mapping), AI applications in radiotherapy , and health policy implementation (e.g., guideline adherence in prostate cancer). Themes include healthcare accessibility, technology assessment, and equity-focused interventions. NIHR Research Fellowship (2014, 2020) NHS National Clinical Impact Award (2022-2026) Wellcome Trust Digital Innovator Award (2021-2023) Advanced Fellowship (2020) Doctoral Research Fellowship (2014-2017) As Editor-in-Chief of the Journal of Cancer Policy , he shapes global discourse. He teaches postgraduate public health students, leads international workshops (CREDO), and trains professionals in radiation oncology quality management. His grants from NIHR, Wellcome Trust, and US NIH support research on AI in radiotherapy and health disparities.
Dr. David Waddington is an NHMRC Emerging Leadership Fellow at the Image X Institute within the Faculty of Medicine and Health at the University of Sydney. He is a member of the University of Sydney Nano Institute and collaborates internationally with institutions like the Martinos Center for Biomedical Imaging at Massachusetts General Hospital. His work focuses on advancing MRI-based imaging technologies for cancer treatment guidance and developing nanoparticle probes for targeted drug delivery. Education: David holds a PhD in Science from the University of Sydney (2018) and earned a University Medal in Physics from UNSW (2010). He was a recipient of a prestigious Postgraduate Fulbright Scholarship (2013–2014) at Harvard University. Research Interests: His projects include the Australian MRI-Linac initiative to improve radiation therapy accuracy through real-time tumor tracking and distortion correction, as well as innovations in low-cost MRI systems and AI-driven image reconstruction. He explores hyperpolarized nanodiamonds for enhanced MRI contrast and synthesizes nanoparticles to improve diagnostic imaging precision in cancer treatment. Key projects: Australian MRI-Linac, MANGO Study, Low-Cost MRI Development International collaborations: Martinos Center (Massachusetts General Hospital) Awards : His achievements include two Best in Physics awards at AAPM (2020, 2022), Summa Cum Laude awards at ISMRM (2016, 2020), and grants such as the FMH Rewarding Research Success (2022) and SEMCAN Viral Bytes Prize (2020). Grants & Students : Leads grants like the 'AI Platform for Targeted Radiotherapy' and 'Advancing Dynamic MRI'. Advises James on developing deep learning techniques for adaptive MRI-guided radiotherapy. His work has produced two patent applications and TEDx talks on medical innovation. Labs/Teams : Affiliated with the ACRF Image X Institute and collaborates with interdisciplinary teams in radiation oncology and biomedical engineering.
Edward Cazalas serves as Assistant Professor in the Civil & Environmental Engineering Department within the University of Utah's College of Engineering. His primary academic appointment began August 2018 following a brief Visiting Assistant Professor role (May-July 2018). He directs the CAZ-RAD research group focused on radiation detection, nuclear security, and radiation effects. His research spans radiation detector development, quantum materials response to radiation, neutron spectrometry, and radiation effects on microelectronics. Key projects include quantum dot radiation response studies, neutron spectrometer development, and FLASH radiotherapy dosimetry. His group operates three specialized laboratories: East Lab (radiation detection electronics), West Lab (reactor-adjacent irradiation testing), and Computational Lab (modeling/simulation). Analysis of his recent publications reveals strong emphasis on quantum materials for radiation detection (perovskite-graphene devices), neutron detection alternatives to helium-3, and radiation effects in nanoscale systems. His work bridges fundamental physics with practical applications in nuclear security, reactor technology, and medical physics. Best Student Paper Award (ANS Radiation Protection Division, 2021) Cazalas has secured over $800,000 in external funding from DOE, DoD, and NIH for radiation effects research, including NNSA Consortium grants and STTR awards with InnoSys Inc. He advises multiple PhD and MS students, with recent graduates including Teancum Quist, Codey Olson, and Jesse Snow. His group maintains strong industry and national laboratory collaborations while operating within the University of Utah's TRIGA Reactor facility and Nanofab Labs. The CAZ-RAD group recently completed major infrastructure projects including installation of a pre-WWII steel shielding cave and PuBe neutron irradiation facility. Current initiatives focus on quantum dot radiation response, radiation-hardened stepper motors, and electron/photon emulation machines.
Dr. Angel Velarde Lopez is a physician, researcher, and professor based in Guatemala, with dual expertise in medical physiology and clinical epidemiology. He holds a faculty position at the School of Medicine, University of San Carlos de Guatemala, and serves as the Department Director of Research at Liga Nacional Contra el Cáncer. He earned a Master of Science in Clinical Epidemiology from the University of Pennsylvania through an NIH scholarship, mentored by Dr. Brian L. Strom. Medical Degree: University of San Carlos School of Medicine, Guatemala MSCE: University of Pennsylvania, NIH Scholarship Continuing Education: Harvard School of Medicine (Electrocardiography) His research focuses on global oncology , particularly cancer epidemiology, radiotherapy access, and health disparities in low- and middle-income countries. He has led and contributed to studies on breast, colon, liver, and brain cancers, with a strong emphasis on improving treatment quality and equity. His work in radiotherapy modernization in Guatemala — transitioning from cobalt-60 to linear accelerators — has been widely published and recognized as a model for LMICs. Dr. Velarde’s recent publications reveal a consistent focus on cancer care delivery , predictive modeling (e.g., Lynch Syndrome), antimicrobial resistance , and implementation science . His collaborative research spans institutions in the U.S., Guatemala, and Taiwan, reflecting a transnational approach to global health challenges. His work often integrates clinical medicine with public health and health systems research. Scientific Awards: NIH Scholarship for MSCE at University of Pennsylvania Dr. Velarde has been actively involved in mentoring and global health education initiatives. He has contributed to simulation-based medical training and has worked on projects funded by international collaborations, including partnerships with the University of Pennsylvania’s Center for Global Health. While no formal list of advisees is provided, his leadership roles suggest active involvement in training future physicians and researchers. He is a key figure in advancing cancer research and treatment in Guatemala, working at the intersection of clinical practice, epidemiology, and health policy. His leadership in radiotherapy quality improvement and cancer epidemiology underscores his role in building sustainable oncology infrastructure in resource-limited settings.
Janggun Jo, Ph.D., is a Research Assistant Professor at the University of Michigan's Department of Biomedical Engineering within the College of Engineering. His work focuses on advancing biomedical imaging technologies with a specialized emphasis on photoacoustic imaging applications. Research Interests: Bio-Nanotechnology Biomedical Imaging and Optics Functional and Molecular Imaging Biomedical Optics Key Research Trends: Recent publications highlight his expertise in developing activatable tumor imaging probes, optimizing photoacoustic oxygen/pH/ion imaging for cancer diagnostics, and pioneering deep learning systems for arthritis assessment. His work bridges nanotechnology with clinical imaging applications, particularly in inflammatory arthritis and oncology. Technical Contributions: Innovations include SwinDAF3D for 3D ultrasound analysis, potassium/sodium nanosensors, and multimodal imaging systems integrating photoacoustic and Doppler ultrasound technologies.
Ash Parameswaran is a Professor and Undergraduate Curriculum Chair in the School of Engineering Science at Simon Fraser University's Faculty of Applied Sciences. He holds a Ph.D. from the University of Alberta (1990), an M.Sc. from the same institution (1985), and a B.E. (Hons) from Madras University, India (1982). His research focuses on microelectronics, MEMS, microfluidics, and biomedical microdevices, with applications in pathogen detection and medical diagnostics. He is also involved in advancing technologies for radiotherapy monitoring and flexible sensor systems. Key research areas include silicon micromachining, microphotonics, and the development of microfluidic platforms for isolating circulating tumor cells and detecting hormones. His work integrates nanotechnology and biomedical engineering principles to create innovative diagnostic tools and sensors. Recent projects involve smartphone-based ELISA systems and electrical impedance-based monitoring for radiation therapy. Prof. Parameswaran has contributed to over 50 peer-reviewed publications, spanning topics from MEMS actuators to medical imaging systems. His academic leadership includes curriculum development and fostering interdisciplinary collaboration across engineering and health sciences. While not currently teaching, he has mentored numerous graduate students in experimental and applied research. His technical expertise extends to antenna design and materials science, with notable contributions to self-assembled millimeter-wave antennas and flexible conductive polymer electrodes. Collaborative projects include low-cost pathogen detection systems and optofluidic biomedical imaging technologies.
Dr. Timothy Owen is an Assistant Professor and Regular Attending Staff at Kingston Health Sciences Centre. His clinical expertise focuses on stereotactic lung CNS radiotherapy and the education of medical students and residents. His research emphasizes advancing stereotactic radiotherapy techniques, particularly in stage I non-small cell lung cancer (NSCLC) and brain metastases management. He leads the LUSTRE trial comparing stereotactic body radiotherapy (SBRT) with conventional hypofractionated radiotherapy (CRT), and has contributed to population-based studies on NSCLC treatment patterns in Ontario. Key research themes include long-term toxicity analysis of radiotherapy protocols, risk factors for intracranial metastasis in NSCLC, and outcomes of hypofractionated treatments. His work extends to transplantation medicine, exploring low-dose aspirin’s role in preventing allograft rejection and IVIG/steroid therapies for immune-related complications. Dr. Owen has also analyzed arterial conduit management in liver transplants and surgical complication economics in hepatopancreaticobiliary surgeries. Publications span over 30 years, with recent focus on SBRT credentialing, brain metastasis outcomes, and radiation therapy optimization. His contributions bridge clinical practice, translational research, and healthcare policy, aiming to improve cancer treatment efficacy and patient safety.
David K. Gaffney is a Professor in the Department of Radiation Oncology at the University of Utah and serves as Senior Director for Clinical Research at the Huntsman Cancer Institute . He holds the J Robert and Ann K Stewart Endowed Professorship and specializes in the radiotherapeutic management of gynecological cancers, breast cancers, and lymphomas. Education: PhD in Biochemistry (1990), MD (1992) - Medical College of Wisconsin Residency - University of Utah School of Medicine Internship - LDS Hospital, Salt Lake City Dr. Gaffney’s research focuses on clinical trial development , prognostic markers , radiation sensitizers , and secondary cancers . His work addresses improving survival and quality of life for cancer patients through optimized radiation protocols and global health initiatives. Recent publications emphasize brachytherapy for cervical cancer, IMRT applications, and financial implications of treatment regimens. He chairs the Clinical Research Executive Committee at Huntsman Cancer Institute and contributes as a Senior Editor for journals like International Journal of Gynecologic Cancer . Dr. Gaffney actively collaborates with international organizations such as the Gynecologic Cancer Intergroup and has led guidelines for cervical and endometrial cancer staging and treatment.
Jaewon Yang is a Professor in the Department of Radiology at UT Southwestern Medical Center, where he leads the Yang Lab focused on advanced radionuclide imaging technologies. Previously, he held roles at Stanford University and UCSF, contributing to PET-guided radiotherapy and quantitative PET imaging techniques. His research emphasizes overcoming clinical challenges in PET/SPECT imaging through deep learning and translational research. Key areas include attenuation correction, motion management, and AI-driven image reconstruction. Dr. Yang's work spans collaborations with institutions like GE Healthcare and RefleXion Medical, advancing technologies such as pseudo-CT generation and emission-guided radiation therapy. His lab integrates clinical needs with innovative solutions, aiming to translate research into commercial products. Recent efforts focus on deep learning applications for PET/MRI and SPECT myocardial perfusion imaging. Publications highlight advancements in PET/SPECT reconstruction, attenuation correction, and AI integration, reflecting a commitment to improving diagnostic precision and clinical workflows. The Yang Lab actively recruits post-doctoral fellows and graduate students to advance these goals.
Tomos Robinson is a researcher at Newcastle University with expertise in health economics, public health policy, and quality of life measurement. His work focuses on economic evaluations of healthcare interventions, particularly in Adolescent weight-specific health metrics Cancer treatment cost-effectiveness Dementia care economics Policy implementation in NHS services His recent research includes methodological innovations in Matching-Adjusted Indirect Comparisons and Time Trade-Off valuations for health states. Collaborative projects span diverse areas like Photobiomodulation for oncology Autism healthcare delivery Childhood obesity policy Pharmaceutical appraisal for NICE Robinson contributes to health technology assessments and collaborates with multidisciplinary teams across epidemiology, clinical medicine, and social policy frameworks.
Rifat Atun is a Professor of Global Health Systems at Harvard University and Faculty Chair of the Harvard Ministerial Leadership Program. He previously held roles as Professor of International Health Management and Head of the Health Management Group at Imperial College London (2006–2013), and served as Director of Strategy, Performance, and Evaluation at The Global Fund to Fight AIDS, Tuberculosis, and Malaria (2008–2012), overseeing $4 billion annually in over 100 countries. His expertise spans global health systems, health policy, and infectious disease control. Education background includes a medical degree (M.B., B.S.), though specific institutions are not detailed. Research focuses on health system strengthening, universal health coverage, antimicrobial resistance, and cancer care equity. He has published over 400 papers in top journals like The Lancet and led 12 Lancet Commissions. Notable contributions include frameworks for digital health education and global maternal health typologies. He advises governments and organizations such as the World Bank, WHO, and UK DFID on health system reforms. Awards include recognition as a Web of Science Highly Cited Researcher (2020). His work bridges academia and policy, emphasizing practical solutions for global health challenges. Key Areas: Global Health Systems, Health Policy, HIV/AIDS, Tuberculosis, Digital Health, Cancer Control Recent Projects: Lancet Commissions on Radiotherapy, Theranostics, and Antimicrobial Resistance Collaborations: WHO, World Bank, Novartis, GSK, and the Vodafone Group
